heredERA Breast Cancer: Phase III study of first-line, fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection +/- giredestrant (GDC-9545) for estrogen receptor+, HER2+advanced breast cancer
CANCER RESEARCH(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要